You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 1
  • CE-45 Baseline factors predictive of the occurrence of neuropsychiatric damage accrual in latin american patients with systemic lupus erythematosus

Article Text

Article menu

Download PDFPDF

Clinical Epidemiology and Outcomes Research
CE-45 Baseline factors predictive of the occurrence of neuropsychiatric damage accrual in latin american patients with systemic lupus erythematosus
Free
  1. Bernardo A Pons-Estel1,
  2. Daniel Wojdyla2,
  3. Graciela S Alarcón3,
  4. Guillermo J Pons-Estel4,
  5. Manuel F Ugarte-Gil5,
  6. Francisco Caeiro6,
  7. Enrique R Soriano7,
  8. Mercedes A García8,
  9. João C Tavares Brenol9,
  10. Eloisa Bonfa10,
  11. Fernando Cavalcanti11,
  12. Gloria Vásquez12,
  13. Marlene Guibert-Toledano13,
  14. Oscar Neira14,
  15. Mario H Cardiel15,
  16. Virginia Pascual-Ramos16,
  17. María I Segami M17,
  18. María H Esteva-Spinetti18 and
  19. Leonor A Barile-Fabris19
  1. 1Hospital Provincial de Rosario, Rosario, Argentina
  2. 2GLADEL consultant, Rosario, Argentina
  3. 3Department of Medicine, Division of Clinical Immunology and Rheumatology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States
  4. 4Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic, Spain
  5. 5Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Perú
  6. 6Servicio de Reumatología, Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina
  7. 7Sección de Reumatología, Servicio de Clínica Médica, Hospital Italiano and Fundación Dr. Pedro M. Catoggio para el Progreso de la Reumatología, Buenos Aires, Argentina
  8. 8Hospital Interzonal General de Agudos “General San Martín”, La Plata, Argentina
  9. 9Hospital das Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
  10. 10Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
  11. 11Centro de Ciências da Saúde, Universidade Federal de Pernambuco, Brazil
  12. 12Universidad de Antioquia, Hospital Universitario “San Vicente de Paul,” Medellín, Colombia
  13. 13Centro de Investigaciones Médico Quirúrgicas- CIMEQ, Havana, Cuba
  14. 14Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile
  15. 15Centro de Investigación Clínica de Morelia SC, Morelia, Michoacan, México
  16. 16Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” Ciudad de México, México
  17. 17Hospital Nacional “Edgardo Rebagliatti Martins,” Essalud, Lima, Perú
  18. 18Hospital Central de San Cristóbal, San Cristóbal, Venezuela
  19. 19Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México

Abstract

Background Neuropsychiatric (NP) manifestations of systemic lupus erythematosus (SLE) are an important source of morbidity, functional impairment and poor quality of life. Several investigators have examined predictors of overall damage accrual in SLE, but predictors of NP-damage have been infrequently evaluated. The aim of this study was to assess the socio-demographic and disease related factors predictive of the occurrence of NP-damage accrual and its impact on mortality in Latin-American SLE patients with early disease.

Materials and methods We included 1100 patients from the GLADEL (Grupo Latino Americano De Estudio del Lupus) inception cohort, free of NP involvement at cohort entry (baseline) (up to 2-years of disease duration). We examined the relationship between socio-demographic characteristics, early clinical manifestations, disease activity and treatments (during the first 6 months post-baseline), with the development of NP-damage after 6 months post-baseline. NP-damage was measured with the SLICC Damage Index or Neuro-Damage (cognitive impairment or major psychosis, seizures requiring therapy for 6 months, cerebrovascular accident ever, cranial or peripheral neuropathy, transverse myelitis). We excluded from the analysis patients with neurologic involvement at entry or those who were lost to follow up before 6 months have elapsed from baseline or who had died during that time period. Data were recorded in an ARTHROS database.

Statistical analysis Patients who developed and those who did not develop NP-damage were compared using the log-rank test. Independent predictors of NP-damage accrual were identified using a Cox proportional hazard regression model.

Results During a median follow-up time of 47 months, 79 (7.2%) patients developed NP-damage. In the univariable analyses, variables predictive of NP-damage were: cardiovascular disease (4.16 per 100 patient-year of follow up [% pyf] vs. 1.62% pyf in patients without cardiovascular disease, p < 0.001), renal disease (2.92% pyf vs. 1.73% pyf, p = 0.038) and lymphopenia (2.71% pyf vs. 1.90% pyf, p = 0.012). In the multivariable analysis only cardiovascular disease (Yes vs. No) was retained in the model: HR 2.554 (95% CI: 1.580–4.128). During follow-up, mortality was higher in those who developed as compared to those who did not develop NP-damage (12/79, 15.2% vs. 34/1021, 3.3%; p < 0.0001).

Conclusions Cardiovascular disease was predictive of the occurrence of NP-damage. Furthermore, the occurrence of NP-damage was significantly associated with a higher mortality. A better control in the early stages of neurological manifestations (early diagnosis and treatment) is needed to reduce NP-damage and improve survival.

Acknowledgements On behalf of GLADEL.

https://doi.org/10.1136/lupus-2016-000179.123

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.